**Aclaris Therapeutics Reports Financial Results and Operational Updates in Annual Filing**
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on immuno-inflammatory diseases, released its financial results and provided a business update in its annual report. The company reported a net loss of $64.9 million for the year ended December 31, 2025, compared to a net loss of $132.1 million for the year ended December 31, 2024. The company's total revenue was $7.8 million, a decrease from $18.7 million in the prior year. This decrease was primarily due to lower licensing revenue, partially offset by contract research revenue. As of December 31, 2025, Aclaris had cash, cash equivalents, and marketable securities totaling $151.4 million.
The company's research and development expenses increased to $52.6 million in 2025 from $33.6 million in 2024, driven by the advancement of key product candidates, including bosakitug, ATI-052, and ATI-9494. General and administrative expenses remained relatively stable at $22.0 million in 2025 compared to $22.2 million in 2024. Licensing expenses decreased from $12.7 million in 2024 to $5.2 million in 2025, reflecting the timing of milestone payments under licensing agreements. The company also noted a $2.3 million expense related to the revaluation of contingent consideration.
Operationally, Aclaris highlighted the ongoing Phase 2 trial of bosakitug in atopic dermatitis, with top-line data expected in the second half of 2026. Positive interim results were announced from the Phase 1a study of ATI-052 in healthy volunteers, leading to the initiation of Phase 1b proof-of-concept trials in atopic dermatitis and asthma, with top-line data expected in the second half of 2026. The company also anticipates filing an IND application for ATI-9494 in the second half of 2026. As of December 31, 2025, Aclaris had 73 employees, including 69 full-time employees.
Aclaris Therapeutics intends to identify and consummate transactions with third-party partners to further develop, obtain marketing approval for and/or commercialize its product candidates. The company believes its existing cash, cash equivalents, and marketable securities will fund operating expenses and capital expenditure requirements for a period greater than 12 months from the date of the report. However, the company acknowledges the need for additional capital to continue developing its product candidates and supporting discovery efforts. The company's future success depends on its ability to successfully develop its product candidates, obtain regulatory approvals, and secure partnerships for commercialization.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel small and large molecule therapies for immuno-inflammatory diseases. Utilizing its proprietary KINect drug discovery platform, Aclaris advances biologics and kinase inhibitor candidates targeting validated pathways. Its pipeline includes monoclonal and bispecific antibodies, oral kinase inhibitors, and topical treatments. The company serves patients with unmet medical needs through research, development, and strategic partnerships, relying on third-party manufacturing and regulatory approvals.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.